SCHEMBL23539711

SCHEMBL23539711

COC(=O)c1cc(C(F)(F)F)c(-c2ccc(F)cc2F)cc1NC(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 1/20 0.41
▸ CFTR P13569 4/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ LMNA P02545 3/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ KDM4E B2RXH2 5/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ GAA P10253 2/20 0.37
▸ STAT1 P42224 1/20 0.37
▸ P2RY1 P47900 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29476287 1.00 ALPL (0.41) ALPLCFTRSMN1; SMN2LMNARAB9A
SCHEMBL29654688 0.88 KDM4E (0.44) SMN1; SMN2LMNAMAPTNPC1KDM4E
SCHEMBL23539997 0.88 KDM4E (0.44) SMN1; SMN2LMNAMAPTNPC1KDM4E
SCHEMBL29476278 0.86 SLC6A4 (0.49) CFTRSMN1; SMN2LMNARAB9ANPC1
SCHEMBL23541000 0.86 SLC6A4 (0.49) CFTRSMN1; SMN2LMNARAB9ANPC1
SCHEMBL25484858 0.84 ALPL (0.43) ALPLSMN1; SMN2LMNARAB9AMAPT
SCHEMBL23539577 0.83 ALPL (0.43) ALPLCFTRSMN1; SMN2LMNARAB9A
SCHEMBL29476206 0.83 ALDH1A1 (0.40) ALPLCFTRRAB9AMAPTNPC1
SCHEMBL23539849 0.83 ALDH1A1 (0.40) ALPLCFTRRAB9AMAPTNPC1
SCHEMBL23539751 0.82 CFTR (0.56) ALPLCFTRMAPTKDM4EPDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162893-B2 Tricyclic pyridones and pyrimidones ERASCA, INC. (US) 2024-12-10 — — US disclosed
US-11845761-B2 Tricyclic pyridones and pyrimidones ERASCA, INC. (US) 2023-12-19 — — US disclosed
EP-4217071-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES Erasca, Inc. (US) 2023-08-02 — — EP disclosed
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-06-29 — — US disclosed
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-06-29 — — US disclosed
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-06-29 — — US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 — — US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 — — US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 — — US disclosed
US-20230107642-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-04-06 — — US disclosed
WO-2022133345-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2022-06-23 — — WO disclosed
WO-2022133345-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2022-06-23 — — WO disclosed
US-20220119409-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2022-04-21 — — US disclosed
US-20220119409-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2022-04-21 — — US disclosed
WO-2021127404-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2021-06-24 — — WO disclosed
WO-2021127404-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES TYMS, TYMP, DHFR ALPL 4740/4885CFTR 2318/4885SMN1; SMN2 1154/4885
US-20220119409-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES DHFR, TYMS, TYMP ALPL 4714/4885CFTR 1960/4885SMN1; SMN2 1205/4885
US-20230107642-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES KRAS, NRAS, HRAS ALPL 4739/4885CFTR 1205/4885SMN1; SMN2 3697/4885
US-11845761-B2 Tricyclic pyridones and pyrimidones KRAS, NRAS, HRAS ALPL 4739/4885CFTR 1205/4885SMN1; SMN2 3697/4885
US-12162893-B2 Tricyclic pyridones and pyrimidones DHFR, TYMS, TYMP ALPL 4714/4885CFTR 1960/4885SMN1; SMN2 1205/4885
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES KRAS, NRAS, HRAS ALPL 4739/4885CFTR 1205/4885SMN1; SMN2 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback